Safety and Insomnia Factors. Another Anavex 2-73 market?
The profound efficacy of Anavex 2-73 to effectively allow people with insomnia to resume normal sleep is, of yet, not properly factored into future AVXl values.
Two matters of demonstrated value:
A, Anavex 2-73 has proven to cause no disqualifying adverse events. Unlike almost all neuro-active drugs, it has no record of disqualifying side effects, as proven in the P1/P2 Australian clinical data. The stuff is utterly safe.
B, In that same clinical trial, it demonstrated universal, complete treatment of insomnia.
What, then, if Anavex 2-73 were to be proposed as a new prescription insomniac? Insomnia is a major public health issue, causing all sorts of untoward outcomes, at great cost. The market for a safe, effective treatment for this mental health scourge is gigantic.
Were that to occur, were it to come to market as an insomniac, might it be subsequently discovered that those treating their insomnia with the Anavex drug subsequently had reduced rates of CNS disease onset? (Incidental CNS disease prophylaxis?)
News 
Market Data 
Discover 
